Payment overview · 2025
General Payments
$537.96
20 reported records · 13 companies
Healthcare provider profile · identity verified
Michael A Blum, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT SAINT LUCIE, FL · NPI 1922082965
Verified facts
What the public records show
CMS Open Payments records show Michael A Blum, D.O. received $537.96 in general payments during 2025 across 20 reported records.
Astellas Pharma US Inc accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $99.00 | 18.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.08 | 13.2% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $51.87 | 9.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.12 | 9.5% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $43.21 | 8.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.02 | 8.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.54 | 7.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.39 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.96 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.29 | 4.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.33 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.05 | 3.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.10 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $438.96 | 19 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $51.87 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.12 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.32 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 85 |
| Eliquis | Apixaban | 210 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 59 |
| Losartan Potassium | Losartan Potassium | 183 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 72 |
| Furosemide | Furosemide | 142 | 50 |
| Lisinopril | Lisinopril | 141 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 45 |
| Gabapentin | Gabapentin | 114 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 37 |
| Metformin Hcl | Metformin Hcl | 101 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 34 |
| Omeprazole | Omeprazole | 86 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 85 | 15 |
| Potassium Chloride | Potassium Chloride | 82 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 29 |
| Donepezil Hcl | Donepezil Hcl | 69 | 15 |
| Simvastatin | Simvastatin | 69 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 24 |
| Alprazolam | Alprazolam | 63 | 23 |
| Trazodone Hcl | Trazodone Hcl | 60 | 27 |
| Prednisone | Prednisone | 58 | 29 |
| Clonidine Hcl | Clonidine Hcl | 55 | 26 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Levetiracetam | Levetiracetam | 53 | 12 |
| Clonazepam | Clonazepam | 50 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 14 |
| Carvedilol | Carvedilol | 42 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 13 |
| Anastrozole | Anastrozole | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 17 |
| Montelukast Sodium | Montelukast Sodium | 39 | 13 |
| Temazepam | Temazepam | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 20 |
| Glipizide | Glipizide | 37 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 12 |
| Finasteride | Finasteride | 32 | 14 |
| Famotidine | Famotidine | 31 | 13 |
| Meloxicam | Meloxicam | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 29 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Atenolol | Atenolol | 24 | 13 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 13 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Captopril | Captopril | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Azithromycin | Azithromycin | 16 | 14 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $537.96 · 20 records | Astellas Pharma US Inc | AIRSUPRA, Arikayce, BREZTRI, Brinsupri, Cologuard Collection Kit, DAYBUE, INTELLIS ADAPTIVESTIM, Korlym, LEQVIO, Leqembi, TRELEGY ELLIPTA, UBRELVY, VYNDAQEL, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error